Skip to main content

#162028

Melan-pe1 cell line

Cat. #162028

Melan-pe1 cell line

Cat. #: 162028

Availability: 8-10 weeks

Organism: Mouse

Tissue: Skin

Disease: Hermansky-Pudlak syndrome

Model: Immortalised non-cancerous cell lines

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Elena Sviderskaya

Institute: St. George's University London

Tool Details
Applications
Handling

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Melan-pe1 cell line
  • Organism: Mouse
  • Tissue: Skin
  • Disease: Hermansky-Pudlak syndrome
  • Morphology: Small, oval-fusiform
  • Model: Immortalised non-cancerous cell lines
  • Description: The melan-pe1 line is an immortal melanocyte cell line derived from neonatal Ap3b1pe/Ap3b1pe C57BL/6J mice. These cell lines lack Ap3b1, a subunit of the adapter protein-3 (AP-3) complex. AP-3 is involved in sorting the key melanogenic enzyme tyrosinase from early-endosomes towards melanosomes. Pathogenic variants in the human ortholog of Ap3b1 cause a form of Hermansky-Pudlak syndrome (HPS), HPS-2. HPS is a group of disorders characterised by hypopigmentation, bleeding tendency and other variable symptoms. These cells are a useful model for HPS and for the study of trafficking of cargoes towards melanosomes.
  • Application: Melanocyte cell biology

Applications

  • Application: Melanocyte cell biology

Handling

  • Growth medium: RPMI + FBS (10%) + TPA (200 nM) + cholera toxin (CT) (200 pM)
  • Storage conditions: liquid N2

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.